
Switzerland paves the way for genome editing
Following in the footsteps of the UK, Switzerland wants to exempt genome editing and targeted mutagenesis in plant breeding from the Swiss Genetic...

EMA delays Valneva vaccine approval
The CHMP’s action puts pressure on the French-Austrian vaccine developer, which wanted to market the vaccine from April on as the UK has already...

Engimmune Therapeutics raises CHF15.5m in seed financing
Pureos Bioventures and Novo Holdings co-led the financing of Engimmune Therapeutics, a spin-off from the research group of Prof. Sai Reddy at the...

Affimed prices public offering to finance NK cell trials
German Affimed N.V. has priced its previously announced public offering of 22,500,000 common shares at a $4.00 per common share. A 30-day...

Hot of the press: BIOTECH Insight Newsletter
According to the results of the Biotechnology Company Survey 2022 conducted by BIOCOM AG (Berlin), the turnover of the German biotech sector grew...

Switzerland shows sustained growth of biotech sector
Capital investments in Swiss biotech companies reached the second-best amount ever with CHF3.33bn in the second year of the pandemic, according to...